Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
retina
Biotech
Lilly bags eye-catching gene therapy in $475M deal
The Indiana drugmaker will gain rights to a gene therapy that has restored vision in 11 children born legally blind.
Darren Incorvaia
Nov 10, 2025 7:00am
Boehringer inks another eye disease deal, this time with Palatin
Aug 18, 2025 10:30am
Atsena gene therapy hits safety goals, closes retinal splits
May 19, 2025 12:59pm
Regeneron snaps up eye biotech, snaring science but not staff
Jan 2, 2025 3:58pm
Atsena downsizes to funnel money toward new capsid program
Oct 5, 2023 1:47pm
Zeiss, Boehringer eye retinal disease-focused predictive AI pact
Oct 2, 2023 1:00pm